Latest & greatest articles for budesonide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on budesonide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on budesonide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for budesonide

81. Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study

Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study Andersson F, Stahl E, Barnes P J, Lofdahl C G, O'Byrne P M, Pauwels R A, Postma D S, Tattersfield A E, Ullman A Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four treatments for patients with persistent symptoms of asthma were examined: low-dose budesonide (total daily dose 200 microg) plus placebo; low-dose budesonide plus formoterol (total daily dose 24 microg); moderate-dose budesonide (total daily dose 800 microg) plus placebo

2001 NHS Economic Evaluation Database.

82. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. (Abstract)

Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. Antiinflammatory therapies, such as inhaled corticosteroids or nedocromil, are recommended for children with asthma, although there is limited information on their long-term use.We randomly assigned 1041 children from 5 through 12 years of age with mild-to-moderate asthma to receive 200 microg of budesonide (311 children), 8 mg of nedocromil (312 children), or placebo (...) (418 children) twice daily. We treated the participants for four to six years. All children used albuterol for asthma symptoms.There was no significant difference between either treatment and placebo in the primary outcome, the degree of change in the forced expiratory volume in one second (FEV1, expressed as a percentage of the predicted value) after the administration of a bronchodilator. As compared with the children assigned to placebo, the children assigned to receive budesonide had

2000 NEJM Controlled trial quality: uncertain

83. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis

Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis Stahl E, van Rompay W, Wang E C, Thomson D M Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Budesonide aqueous nasal spray and fluticasone propionate allergic spray in the treatment of perennial allergic rhinitis (PAR). Type of intervention Treatment. Economic study type Cost

2000 NHS Economic Evaluation Database.

84. Budesonide in the treatment of Crohn's disease: a meta-analysis

Budesonide in the treatment of Crohn's disease: a meta-analysis Budesonide in the treatment of Crohn's disease: a meta-analysis Budesonide in the treatment of Crohn's disease: a meta-analysis Papi C, Luchetti R, Gili L, Montanti S, Koch M, Capurso L Authors' objectives To perform a meta-analysis to assess the effectiveness and safety of oral budesonide for inducing remission in active Crohn's disease and for preventing relapse in Crohn's disease with medically- or surgically-induced remission (...) . Searching MEDLINE (from initiation to date of search) was searched using the following MeSH terms: 'budesonide' and 'Crohn' or 'inflammatory bowel disease'. A manual search of review articles and proceedings from major gastrointestinal meetings (1993-1999) was also performed, and the bibliographies of retrieved articles searched. Only results fully reported in journal articles were included. No language restrictions were reported. Study selection Study designs of evaluations included in the review

2000 DARE.

85. A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis

A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis Keith P K, Haddon J, Birch S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Intranasal budesonide for seasonal allergic rhinitis. Type of intervention Treatment. Economic study type Cost-benefit analysis. Study population Patients suffering from seasonal allergic rhinitis. Setting Community. The study was carried out in Canada. Dates to which data relate

2000 NHS Economic Evaluation Database.

86. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily (...) and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback B, Jenkins C, Price M J, Thwaites R M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Salmeterol/fluticasone propionate combination

2000 NHS Economic Evaluation Database.

87. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. (Abstract)

Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. Relapses of acute asthma following emergency department (ED) discharge can be reduced with systemic corticosteroid treatment. However, whether inhaled corticosteroids (ICSs) provide additional benefit is not known. Objective To determine whether the addition of ICSs to oral corticosteroid treatment would reduce relapses in patients (...) course of oral prednisone (50 mg/d) for 7 days. In a double-blind fashion, patients were randomly assigned to 1600 microg/d of inhaled budesonide (n = 94) or identical placebo (n = 94) for 21 days.Incidence of relapse, defined as an unscheduled visit for worsening asthma symptoms, in budesonide vs placebo groups. Secondary outcomes included response to the Asthma Quality of Life Questionnaire, beta2-agonist use, symptom score, global asthma improvement assessment, and pulmonary function.Five patients

1999 JAMA Controlled trial quality: predicted high

88. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. (Abstract)

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Little is known about the long-term efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease (COPD). We investigated the efficacy of inhaled budesonide on decline in lung function and respiratory symptoms in a 3-year placebo-controlled study of patients with COPD.We used a parallel-group, randomised, double-blind, placebo-controlled design (...) in a singlecentre study, nested in a continuing epidemiological survey (the Copenhagen City Heart Study). Inclusion criteria were as follows: no asthma; a ratio of forced expiratory volume in 1 s (FEV1) and vital capacity of 0.7 or less; FEV1 which showed no response (<15% change) to 1 mg inhaled terbutaline or prednisolone 37.5 mg orally once daily for 10 days. 290 patients were randomly assigned budesonide, 800 microg plus 400 microg daily for 6 months followed by 400 microg twice daily for 30 months

1999 Lancet Controlled trial quality: predicted high

89. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. (Abstract)

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. Although patients with chronic obstructive pulmonary disease (COPD) should stop smoking, some do not. In a double-blind, placebo-controlled study, we evaluated the effect of the inhaled glucocorticoid budesonide in patients with mild COPD who continued smoking. After a six-month run-in period, we (...) randomly assigned 1277 subjects (mean age, 52 years; mean forced expiratory volume in one second [FEV1], 77 percent of the predicted value; 73 percent men) to twice-daily treatment with 400 microg of budesonide or placebo, inhaled from a dry-powder inhaler, for three years.Of the 1277 subjects, 912 (71 percent) completed the study. Among these subjects, the median decline in the FEV1 after the use of a bronchodilator over the three-year period was 140 ml in the budesonide group and 180 ml

1999 NEJM Controlled trial quality: predicted high

90. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children Full Text available with Trip Pro

The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children Barnes N C, Thwaites R M, Price M J Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technologies were the use of fluticasone propionate (FP) and budesonide (Bud) in the treatment of patients suffering from asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of adult

1999 NHS Economic Evaluation Database.

91. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. (Abstract)

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. Crohn's disease is often treated with glucocorticoids or mesalamine. We compared the efficacy and safety of controlled-ileal-release budesonide capsules and slow-release mesalamine tablets in patients with active Crohn's disease affecting the ileum, the ascending colon, or both.In a double-blind, multicenter trial, we enrolled 182 patients with scores of 200 to 400 (...) on the Crohn's Disease Activity Index (with higher scores indicating greater disease activity) and randomly assigned 93 to receive 9 mg of budesonide once daily and 89 to receive 2 g of mesalamine twice daily for 16 weeks. The primary efficacy variable was clinical remission, defined as a score of 150 or less on the Crohn's Disease Activity Index.In the analysis of all patients who received at least one dose of study drug, the rates of remission after 8 weeks of treatment were 69 percent in the budesonide

1998 NEJM Controlled trial quality: predicted high

92. A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. (Abstract)

A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. In children with croup, treatment with nebulized budesonide decreases symptoms, but it is uncertain how budesonide compares with dexamethasone, the conventional therapy for croup, and whether either reduces the rate of hospitalization.We performed a double-blind, randomized trial involving 144 children with moderately severe croup. The children were treated with racepinephrine (...) and a single dose of 4 mg of nebulized budesonide (48 children), 0.6 mg of intramuscular dexamethasone per kilogram of body weight (47 children), or placebo (49 children). The children were assessed before treatment and then hourly for five hours after treatment. Physicians who were unaware of the treatment assignments determined the children's need for further treatment and hospitalization.The characteristics of the groups were similar at base line, including the types of viruses identified, the types

1998 NEJM Controlled trial quality: predicted high

93. Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial. (Abstract)

Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial. The effectiveness of glucocorticoids for patients with croup is well established but it remains uncertain which glucocorticoid regimen is most effective.To determine the effectiveness of 3 glucocorticoid regimens in patients with croup.Randomized controlled trial with parallel design.Emergency departments of 2 Canadian pediatric tertiary care hospitals.Children with a clinical syndrome consistent (...) with croup, aged 3 months to 5 years, with a croup score of 2 or greater following at least 15 minutes of mist therapy.Oral dexamethasone, 0.6 mg/kg, and nebulized placebo; oral placebo and nebulized budesonide, 2 mg; or oral dexamethasone, 0.6 mg/kg, and nebulized budesonide, 2 mg.Westley croup score (primary outcome), hospital admission rates, time spent in the emergency department, return visits to the emergency department, or ongoing symptoms at 1 week.The mean change in the croup score from baseline

1998 JAMA Controlled trial quality: predicted high

94. Cost effectiveness of fluticasone and budesonide in patients with moderate asthma

Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Steinmetz K O, Volmer T, Trautmann M, Kielhorn A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Inhaled fluticasone (metered dose inhaler) was compared to inhaled budesonide (Turbuhaler(R) in corticosteroid-naive patients with moderate asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The authors did not define the study population. The study sample comprised patients enrolled in a multi-centre trial, who were aged between

1998 NHS Economic Evaluation Database.

95. Cost-effectiveness of budesonide controlled ileal release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohn's disease in Sweden

was SEK101 for the intervention compared with the comparator. The sensitivity analyses established that the results were fairly robust, the largest impact being to the cost of surgery. Authors' conclusions This paper indicates that maintenance therapy with budesonide CIR capsules (Entocort capsules) is a cost-effective alternative to no maintenance treatment. CRD COMMENTARY - Selection of comparators A justification was provided for the choice of the comparator, which was regarded as "a valid treatment (...) Cost-effectiveness of budesonide controlled ileal release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohn's disease in Sweden Cost-effectiveness of budesonide controlled ileal release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohn's disease in Sweden Cost-effectiveness of budesonide controlled ileal release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohn's disease

1998 NHS Economic Evaluation Database.

96. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. (Abstract)

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. The role of long-acting, inhaled beta2-agonists in treating asthma is uncertain. In a double-blind study, we evaluated the effects of adding inhaled formoterol to both lower and higher doses of the inhaled glucocorticoid budesonide.After a four-week run-in period of treatment with budesonide (800 microg twice daily), 852 patients being (...) treated with glucocorticoids were randomly assigned to one of four treatments given twice daily by means of a dry-powder inhaler (Turbuhaler): 100 microg of budesonide plus placebo, 100 microg of budesonide plus 12 microg of formoterol, 400 microg of budesonide plus placebo, or 400 microg of budesonide plus 12 microg of formoterol. Terbutaline was permitted as needed. Treatment continued for one year; we compared the frequency of exacerbations of asthma, symptoms, and lung function in the four groups

1997 NEJM Controlled trial quality: predicted high

97. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. (Abstract)

A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. Inhaled glucosteroids and oral theophylline are widely used to treat asthma. We compared the benefits of adding theophylline to inhaled glucosteroid with those of doubling the dose of inhaled glucosteroid in patients with persistent symptoms despite the use of inhaled glucosteroid.In a double-blind, placebo-controlled trial, we randomly assigned 62 patients to receive either 400 (...) microg of inhaled budesonide (low-dose budesonide) with 250 or 375 mg of theophylline (depending on body weight) or 800 microg of inhaled budesonide (high-dose budesonide). All doses were given twice daily for three months. Lung function was measured serially, and patients kept records of peak expiratory flow, symptoms, and albuterol use. The effects of treatment on endogenous cortisol levels were also assessed.Both treatments resulted in improvements in lung function that were sustained throughout

1997 NEJM Controlled trial quality: predicted high

98. Nebulized budesonide for children with mild-to-moderate croup. (Abstract)

Nebulized budesonide for children with mild-to-moderate croup. Although recent evidence has strongly supported the use of glucocorticoid therapy in children hospitalized with croup, the benefit of this therapy in children with less severe croup has not been documented. This randomized, double-blind trial compared a nebulized glucocorticoid, budesonide, with placebo in outpatients with mild-to-moderate croup.Children three months to five years of age were eligible for the study if their croup (...) scores fell in the mild-to-moderate range (scores of 2 to 7 out of a possible 17). The patients were randomly assigned to receive either 2 mg (4 ml) of nebulized budesonide (27 children) or 4 ml of nebulized normal saline (27 children); they were then assessed hourly for up to four hours by investigators who were unaware of the assigned treatments.The median croup score at entry into the study was 4 in both groups. At the final study assessment, the median score was significantly lower

1994 NEJM Controlled trial quality: predicted high

99. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. (Abstract)

Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. In a previous study, we found that two years of treatment with an inhaled corticosteroid, budesonide, was more effective than treatment with an inhaled beta 2-agonist, terbutaline, in patients with newly diagnosed, generally mild asthma. We continued this study for a third year to investigate whether the steroid dose could be reduced or discontinued and what effect crossover of patients from beta 2-agonist (...) therapy to corticosteroid therapy would have.A total of 37 patients treated for two years with inhaled budesonide at a dose of 1200 micrograms per day were randomly assigned to treatment with 400 micrograms of budesonide per day (19 patients) or placebo (18 patients) in a double-blind manner. Another 37 patients, who had received terbutaline during the first two years, were crossed over in an open-label manner to treatment with 1200 micrograms of budesonide per day during the third year.Treatment

1994 NEJM Controlled trial quality: uncertain

100. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. (Abstract)

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. Corticosteroids are the most efficacious drugs for inducing remission in active Crohn's disease, but their benefits are frequently offset by serious side effects. Budesonide is a corticosteroid with high topical antiinflammatory activity but low systemic activity because of extensive hepatic metabolism. We investigated the efficacy and safety of an oral controlled-ileal-release preparation of budesonide (...) in patients with active Crohn's disease involving the ileum or ileum and proximal colon.In a double-blind, multicenter trial, 258 patients were randomly assigned to receive placebo or one of three doses of budesonide--3, 9, or 15 mg daily. The primary outcome measure was clinical remission, as defined by a score of 150 or less on the Crohn's disease activity index.After eight weeks of treatment, remission occurred in 51 percent of the patients in the group receiving 9 mg of budesonide (95 percent

1994 NEJM Controlled trial quality: predicted high